Nifty
:
24834.85
Sensex
:
81332.72
428.75 (1.76%)
1292.92 (1.62%)
Nifty
Sensex
:
:
24834.85
81332.72
428.75 (1.76%)
1292.92 (1.62%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
63/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
1568.40
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1562.00
  •  1574.75
  •  1557.00
  •  1557.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2481046
  •  38902.16
  •  1723.80
  •  1068.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 411,150.04
  • 42.93
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 403,475.05
  • 0.79%
  • 6.46

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.09%
  • 5.57%
  • FII
  • DII
  • Others
  • 17.23%
  • 17.80%
  • 2.83%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.88
  • 8.11
  • 7.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.07
  • 12.82
  • 5.23

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.76
  • 20.53
  • 42.98

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 35.97
  • 37.46
  • 36.96

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.76
  • 3.86
  • 4.60

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.65
  • 18.68
  • 20.66

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
11,982.90
10,930.67
9.63%
12,380.70
11,240.97
10.14%
12,192.41
10,952.28
11.32%
11,940.84
10,761.76
10.96%
Expenses
8,947.75
8,128.54
10.08%
9,028.43
8,237.25
9.60%
9,013.03
7,995.73
12.72%
8,611.11
8,023.04
7.33%
EBITDA
3,035.15
2,802.13
8.32%
3,352.27
3,003.72
11.60%
3,179.38
2,956.55
7.54%
3,329.73
2,738.72
21.58%
EBIDTM
25.33%
25.64%
27.08%
26.72%
26.08%
26.99%
27.89%
25.45%
Other Income
605.94
373.28
62.33%
374.76
173.88
115.53%
293.61
85.22
244.53%
206.48
147.81
39.69%
Interest
73.57
92.74
-20.67%
34.73
46.18
-24.79%
49.29
19.39
154.20%
80.88
13.69
490.80%
Depreciation
650.36
671.53
-3.15%
622.14
659.95
-5.73%
632.82
609.95
3.75%
651.32
588.00
10.77%
PBT
2,815.52
2,239.69
25.71%
3,000.35
2,471.47
21.40%
2,790.88
2,412.43
15.69%
2,481.14
2,284.84
8.59%
Tax
148.93
222.91
-33.19%
432.32
283.43
52.53%
390.10
152.26
156.21%
468.10
188.99
147.69%
PAT
2,666.59
2,016.78
32.22%
2,568.03
2,188.04
17.37%
2,400.78
2,260.17
6.22%
2,013.04
2,095.85
-3.95%
PATM
22.25%
18.45%
20.74%
19.46%
19.69%
20.64%
16.86%
19.48%
EPS
11.06
8.27
33.74%
10.52
9.03
16.50%
9.90
9.43
4.98%
8.43
8.59
-1.86%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
-
48,496.85
43,885.68
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
Net Sales Growth
-
10.51%
13.53%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
 
Cost Of Goods Sold
-
10,662.61
10,662.16
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
Gross Profit
-
37,834.24
33,223.52
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
GP Margin
-
78.01%
75.70%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
Total Expenditure
-
35,747.77
32,298.12
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
Power & Fuel Cost
-
760.78
830.05
702.78
627.09
621.89
613.60
559.97
525.09
545.44
560.77
% Of Sales
-
1.57%
1.89%
1.82%
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
Employee Cost
-
9,429.06
8,296.03
7,300.83
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
% Of Sales
-
19.44%
18.90%
18.89%
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
Manufacturing Exp.
-
2,186.62
1,936.77
1,880.71
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
% Of Sales
-
4.51%
4.41%
4.87%
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
General & Admin Exp.
-
5,252.93
4,256.12
3,270.55
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
% Of Sales
-
10.83%
9.70%
8.46%
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
Selling & Distn. Exp.
-
5,780.26
5,226.24
4,096.33
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
% Of Sales
-
11.92%
11.91%
10.60%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
Miscellaneous Exp.
-
1,675.51
1,090.75
1,169.94
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
2,236.40
% Of Sales
-
3.45%
2.49%
3.03%
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
EBITDA
-
12,749.08
11,587.56
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
EBITDA Margin
-
26.29%
26.40%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
Other Income
-
1,628.24
693.75
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
Interest
-
238.47
172.00
127.35
141.43
302.73
555.25
517.57
399.80
523.24
578.99
Depreciation
-
2,556.64
2,529.43
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
PBT
-
11,582.21
9,579.88
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
Tax
-
1,439.45
847.59
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
Tax Rate
-
12.98%
9.01%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
PAT
-
9,614.79
8,521.48
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
PAT before Minority Interest
-
9,648.44
8,560.84
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
Minority Interest
-
-33.65
-39.36
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
PAT Margin
-
19.83%
19.42%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
PAT Growth
-
12.83%
159.07%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
 
EPS
-
40.07
35.52
13.71
12.15
15.75
11.12
8.84
28.99
18.94
18.97

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
63,666.75
55,995.38
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
239.93
239.93
240.66
207.12
Total Reserves
63,426.82
55,755.45
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
Non-Current Liabilities
-2,731.14
-1,997.80
-1,316.37
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
Secured Loans
0.00
0.00
0.00
7.83
6.18
109.47
217.69
185.59
7.73
40.69
Unsecured Loans
1.33
0.00
229.92
646.88
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
Long Term Provisions
413.89
342.91
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
Current Liabilities
16,983.77
19,906.38
17,208.45
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
Trade Payables
5,653.30
5,681.52
4,489.76
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
Other Current Liabilities
2,716.85
2,603.51
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
Short Term Borrowings
2,844.36
5,958.26
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
Short Term Provisions
5,769.26
5,663.09
9,323.44
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
Total Liabilities
81,358.60
77,224.05
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
Net Block
23,211.38
24,065.44
22,665.16
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
Gross Block
44,283.71
43,099.95
38,707.36
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
Accumulated Depreciation
21,072.33
19,034.51
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
Non Current Assets
37,884.25
37,341.33
32,093.59
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
Capital Work in Progress
5,353.88
4,973.16
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
Non Current Investment
6,441.23
5,451.73
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
Long Term Loans & Adv.
2,784.59
2,757.87
2,880.86
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
Other Non Current Assets
93.17
93.13
46.12
4.67
5.53
21.96
50.21
682.18
953.34
103.94
Current Assets
43,433.11
39,861.94
34,864.60
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
Current Investments
8,584.54
9,372.61
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
Inventories
9,868.29
10,513.05
8,925.13
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
Sundry Debtors
11,249.37
11,438.51
10,484.59
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
Cash & Bank
10,520.68
5,770.29
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
Other Current Assets
3,210.23
745.91
775.01
1,319.11
2,973.02
3,072.69
2,919.93
3,546.51
2,847.64
5,026.16
Short Term Loans & Adv.
2,454.24
2,021.57
2,012.58
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
Net Current Assets
26,449.34
19,955.56
17,656.15
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
Total Assets
81,317.36
77,203.27
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
12,134.98
4,959.33
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
PBT
11,087.89
9,408.43
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
Adjustment
1,554.40
2,722.56
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
Changes in Working Capital
1,062.13
-5,661.82
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
Cash after chg. in Working capital
13,704.42
6,469.17
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,569.44
-1,509.84
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-690.20
-7,943.68
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
Net Fixed Assets
-420.26
-573.97
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
Net Investments
183.27
2,935.63
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
Others
-453.21
-10,305.34
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
Cash from Financing Activity
-6,710.16
2,376.07
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
Net Cash Inflow / Outflow
4,734.62
-608.28
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
Opening Cash & Equivalents
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
Closing Cash & Equivalent
9,285.65
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
265.36
233.38
200.11
193.65
188.66
172.59
159.69
152.70
137.03
123.49
ROA
12.17%
11.88%
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
ROE
16.13%
16.46%
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
ROCE
17.60%
17.24%
9.28%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
Fixed Asset Turnover
1.11
1.07
1.81
1.74
1.78
1.92
1.99
1.29
1.34
1.79
Receivable days
85.38
91.17
53.09
54.88
56.22
54.10
53.53
83.25
76.12
48.20
Inventory Days
76.70
80.83
48.68
50.10
48.40
47.84
48.88
78.98
77.46
57.99
Payable days
194.01
174.10
149.21
158.71
152.86
77.81
90.19
85.47
75.24
52.05
Cash Conversion Cycle
-31.93
-2.10
-47.44
-53.73
-48.24
24.13
12.23
76.75
78.34
54.14
Total Debt/Equity
0.04
0.11
0.02
0.08
0.18
0.25
0.27
0.27
0.26
0.35
Interest Cover
47.50
55.70
36.19
20.79
17.55
7.86
7.72
23.63
13.56
12.06

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Sun Pharmaceutical gets USFDA’s nod for LEQSELVI tablets
    26th Jul 2024, 14:25 PM

    LEQSELVI is a new, twicedaily oral selective inhibitor of Janus Kinases (JAK) JAK1 and JAK2

    Read More
  • Sun Pharmaceutical completes merger of Taro Pharmaceutical Industries
    24th Jun 2024, 17:50 PM

    As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates

    Read More
  • Sun Pharma enters into patent licensing agreement with Takeda Pharmaceutical
    21st Jun 2024, 09:22 AM

    Under the terms of this agreement, Takeda has granted Sun Pharma non-exclusive patent licensing rights for the commercialization of Vonoprazan in India

    Read More
  • Sun Pharmaceutical Industries gets warning letter from USFDA for Dadra facility
    20th Jun 2024, 09:50 AM

    The Warning Letter summarizes violations with respect to Current Good Manufacturing Practice regulations

    Read More
  • Sun Pharma to acquire 9.6% stake in HaystackAnalytics
    7th Jun 2024, 09:20 AM

    The said acquisition is expected to be completed by July 2024 subject to satisfactory completion of certain conditions

    Read More
  • Sun Pharma’s arm recalls 35,069 bottles of Xelpros
    31st May 2024, 14:29 PM

    The company initiated the voluntary Class III recall in the US on April 22 this year

    Read More
  • Sun Pharmaceutical Industries reports 34% rise in Q4 consolidated net profit
    23rd May 2024, 17:19 PM

    Total consolidated income of the company increased by 11.37% at Rs 12,588.84 crore for Q4FY24

    Read More
  • Sun Pharma Inds. - Quarterly Results
    22nd May 2024, 15:19 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.